The pattern of risk of myocardial infarction in patients taking asthma medication: A study with the General Practice Research Database

Journal of Hypertension

Volumn 27, Issue 7, 2009, Pages 1485-1492

  Zhang, Bill ^a   De Vries, Frank ^a,b   Setakis, Efrosini ^a   Van Staa, Tjeerd Pieter ^a,b  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Asthma; Beta2 agonists; Inhaled corticosteroids; Myocardial infarction

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; SALMETEROL; XANTHINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ASTHMA; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; POWDER INHALER; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 67649809852     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832af68d     Document Type: Article

References (21)

1. Anderson PJ, Zhou X, Breen P, Gann L, Logsdon TW, Compadre CM, Hiller FC. Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers. J Pharm Sci 1998; 87:841-844.
2. Hoffman B, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Hardman J, Limbird L, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill; 2002. p. 141.
3. Breeden CC, Safirstein BH. Albuterol and spacer-induced atrial fibrillation. Chest 1990; 98:762-763.
4. Vincent HH, Veld AJ, Boomsma F, Schalekamp M. Prevention of epinephrine-induced hypokalemia by nonselective beta blockers. Am J Cardiol 1985; 56:10D-14D.
5. Kung M, Croley SW, Phillips BA. Systemic cardiovascular and metabolic effects associated with the inhalation of an increased dose of albuterol. Influence of mouth rinsing and gargling. Chest 1987; 91:382-387.
6. Au DH, Curtis JR, Every NR, McDonnell MB, Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 2002; 121:846-851.
7. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 2000; 161:827-830.
8. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008; 3:163-169.
9. Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58:43-46.
10. de Vries F, Pouwels S, Bracke M, Lammers JW, Klungel O, Leufkens H, van Staa T. Use of beta2 agonists and risk of acute myocardial infarction in patients with hypertension. Br J Clin Pharmacol 2008; 65:580-586.
11. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of betaagonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309-2321.
12. Suissa S, Assimes T, Brassard P, Ernst P. Inhaled corticosteroid use in asthma and the prevention of myocardial infarction. Am J Med 2003; 115:377-381.
13. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25:634-639.
14. de Vries F, Pouwels S, Bracke M, Lammers JW, Leufkens H, Klungel O, van Staa T. Use of inhaled corticosteroids and the risk of nonfatal acute myocardial infarction. J Hypertens 2008; 26:124-129.
15. Lö fdahl CG, Postma DS, Pride NB, Boe J, Thore'n A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J 2007; 29:1115-1119.
16. Walley T, Mantgani A. The UK general practice research database. Lancet1997; 350:1097-1099.
17. Soriano JB, Maier WC, Visick G, Pride NB. Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001; 17:1075-1080.
18. Anonymous. British guideline on the management of asthma. Revised edition November 2005. Downloaded http://www.brit-thoracic.org.uk/ Portals/0/ Clinical%20Information/Asthma/Guidelines/ asthmaupdatenov05.pdf.
19. Anderson KM, Odell PM, Wilson WF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1990; 121:293-298.
20. Ramlau-Hansen H. Smoothing counting process intensities by means of kernel functional. Ann Statist 1983; 11:453-466.
21. Ferguson GT, Calverly PMA, Anderson JA, Celli B, Jenkins C, Jones PW, et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) is well tolerated in patients with COPD over three years. Eur Respir J 2006; 28 (Suppl 50):34s.